> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly Validates CDK4/6 Continuation in ESR1 Breast Cancer at an 86% Toxicity Cost
- URL: https://bioweek.com/lilly-validates-cdk4-6-continuation-in-esr1-breast-cancer-at-an-86-toxicity-cost/
- Published: 2026-09-20T05:04:46.000Z
- Updated: 2026-09-20T05:04:46.000Z
- Description: FDA approved Lilly's Inluriyo plus Verzenio for ESR1-mutated ER+/HER2- metastatic breast cancer after endocrine progression, doubling median PFS to 11.1 months in EMBER-3. The clinical gain comes with 86% diarrhea and neutropenia rates, challenging early liquid biopsy switching models.
- Author: BioWeek
- Tags: Pipeline, Science

The U.S. Food and Drug Administration on September 18, 2026 [approved](https://www.prnewswire.com/news-releases/us-fda-approves-inluriyo-imlunestrant-in-combination-with-verzenio-abemaciclib-for-adults-with-er-her2--esr1-mutated-advanced-or-metastatic-breast-cancer-302252194.html?ref=bioweek.com) Eli Lilly's Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-negative), ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, after disease progression following at least one line of endocrine therapy. The decision is Inluriyo's second FDA approval in under a year. The oral selective estrogen receptor degrader first reached the market as monotherapy in September 2025.

The combination label is grounded in the Phase 3 EMBER-3 [trial](https://clinicaltrials.gov/study/NCT04975308?ref=bioweek.com) (NCT04975308). In patients with ESR1-mutated metastatic breast cancer (n=159) who had progressed on an aromatase inhibitor with or without a CDK4/6 inhibitor, 92 received Inluriyo monotherapy and 67 received Inluriyo plus Verzenio. Dual therapy doubled median progression-free survival: 11.1 months versus 5.5 months on Inluriyo alone. The hazard ratio was 0.53 (95% CI: 0.35-0.80). Dr. Komal Jhaveri, section head of the Endocrine Therapy Research Program at Memorial Sloan Kettering Cancer Center and principal investigator of EMBER-3 and EMBER-4, led the study.

### ESR1 mutations and a modest oral SERD benchmark

In ER-positive, HER2-negative metastatic breast cancer, up to 50% of patients previously treated with endocrine therapy develop activating mutations in ESR1, the gene that encodes the estrogen receptor alpha subunit. Those mutations drive ligand-independent constitutive ER signaling and confer resistance to aromatase inhibitors. Lilly's combination is arriving into a market that already has an oral SERD. Menarini's Orserdu (elacestrant) was approved in January 2023 as monotherapy, but delivered a modest median PFS of only 3.8 months in ESR1-mutated patients, versus 1.9 months with standard endocrine therapy. Eleven months of median PFS on Inluriyo plus Verzenio is a different magnitude of control, though the two trials are not head-to-head.

### The CDK4/6 continuation debate

Oncologists have long argued over whether continuing or switching CDK4/6 inhibition after disease progression provides genuine clinical benefit or merely compounds toxicity without altering tumor biology. EMBER-3 shows that degrading mutated estrogen receptor while blocking CDK4/6 restores cell cycle control and doubles PFS relative to the SERD alone. That finding will pressure clinics that drop CDK4/6 inhibitors at first radiographic progression in ESR1-mutated disease.

A related controversy sits in diagnostics. Several firms and trials, including PADA-1, have advocated serial circulating tumor DNA blood testing to catch emerging ESR1 mutations and switch therapy before radiologic progression. Jacob Van Naarden, executive president and president of Lilly Oncology, challenged that practice on approval: "In fact, all available evidence suggests that switching endocrine therapy and CDK4/6 inhibitor at clinical progression improves patient outcomes more than switching therapy earlier. Utilizing this evidence-based practice spares early exposure to additional side effects, reduces patient anxiety from unnecessary testing, and mitigates avoidable costs to the healthcare system."

### An 86% toxicity bill

The efficacy gain is not free. In the EMBER-3 combination arm, diarrhea occurred in 86% of patients (Grade 3 or 4: 9%). Neutrophil count decreased in 86% (Grade 3 or 4: 21%). Alanine aminotransferase increased in 33% (Grade 3/4: 5%). Aspartate aminotransferase increased in 36% (Grade 3/4: 2.5%). Serum creatinine increased in 36% (Grade 3/4: 1.1%). Venous thromboembolic events occurred in 4.8%. Interstitial lung disease or pneumonitis occurred in 2.9%.

Serious adverse reactions occurred in 21% of patients, including pneumonia (2.4%), abdominal pain (1.4%), and renal failure (1.4%). Fatal adverse reactions occurred in 3.8% of patients: pneumonia 1.4%, myocardial infarction 0.5%, ILD 0.5%, and sepsis 0.5%. Permanent discontinuation of Inluriyo alone due to adverse reactions was 1%; permanent discontinuation of Verzenio alone was 3.4%. The 86% diarrhea and neutropenia rates will shape who stays on dual therapy in community practice, even if few patients drop the drugs outright.

### Dosing and the adjuvant horizon

Inluriyo is an oral tablet taken once daily as 400 mg (two 200 mg tablets) on an empty stomach, at least 2 hours before or 1 hour after food. Verzenio is taken twice daily. Use requires an FDA-authorized test to confirm an ESR1 mutation.

Lilly is already running the much larger Phase 3 EMBER-4 [study](https://clinicaltrials.gov/study/NCT05514054?ref=bioweek.com) (NCT05514054), enrolling more than 8,000 patients across more than 650 sites in more than 30 countries in the adjuvant setting for high-risk ER-positive, HER2-negative early breast cancer. Initial data are anticipated in 2027\. If EMBER-4 reads out positively, the metastatic combination approval becomes a bridge to a far larger early-disease franchise. For now, the metastatic data settle a narrower but commercially and clinically important question: after endocrine progression in ESR1-mutated disease, keeping CDK4/6 blockade on board with a next-generation oral SERD can double the time before the next progression, if patients and physicians can absorb the gastrointestinal and hematologic cost.